Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms RESGEX
- Sponsors Glycotope
- 25 Jul 2017 Planned End Date changed from 1 Jul 2017 to 15 Dec 2017.
- 25 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 30 Sep 2017.
- 08 Jul 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.